Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder
- DOI
- 10.1212/nxi.0000000000200609
- Published
- 2026-09
- Container
- Neurology Neuroimmunology & Neuroinflammation
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1212/nxi.0000000000200609,
title = {Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder},
author = {Sean J. Pittock and Michael H. Barnett and Jeffrey L. Bennett and Achim Berthele and Jérôme de Sèze and Michael Levy and Ichiro Nakashima and Celia Oreja-Guevara and Jacqueline Palace and Friedemann Paul and Carlo Pozzilli and Ritu Pathak and Kerstin Allen and Becky Parks and Ho Jin Kim},
year = {2026},
journal = {Neurology Neuroimmunology \& Neuroinflammation},
doi = {10.1212/nxi.0000000000200609},
url = {https://doi.org/10.1212/nxi.0000000000200609}
}RIS
TY - JOUR TI - Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder AU - Sean J. Pittock AU - Michael H. Barnett AU - Jeffrey L. Bennett AU - Achim Berthele AU - Jérôme de Sèze AU - Michael Levy AU - Ichiro Nakashima AU - Celia Oreja-Guevara AU - Jacqueline Palace AU - Friedemann Paul AU - Carlo Pozzilli AU - Ritu Pathak AU - Kerstin Allen AU - Becky Parks AU - Ho Jin Kim PY - 2026 JO - Neurology Neuroimmunology & Neuroinflammation DO - 10.1212/nxi.0000000000200609 UR - https://doi.org/10.1212/nxi.0000000000200609 ER -
APA
Pittock, S. J., Barnett, M. H., Bennett, J. L., Berthele, A., Sèze, J. D., Levy, M., Nakashima, I., Oreja-Guevara, C., Palace, J., Paul, F., Pozzilli, C., Pathak, R., Allen, K., Parks, B., & Kim, H. J. (2026). Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000200609
Source records
- crossref · retrieved 2026-09-26T09:28:48.802Z